This site is intended for health professionals only!
Lundbeck announces 2009 results, which meet financial forecasts and continue to show growth in all regions.
Full year revenue was DKK 13,747 million and increased by 22% at constant exchange rates compared to 2008. Growth was driven by key products and the acquisition of Ovation Pharmaceuticals, Inc. (now Lundbeck Inc.).
Going into 2010 Lundbeck has three products Azilect, Xenazine and Sabril with the potential to be significant contributors to revenue and growth.
Cipralex, Ebixa and Azilect continue to show strong growth by 12%, 17% and 43% respectively. Lexapro was up 9%.
Xenazine contributed DKK 298 million in the 9 months, following the acquisition of Ovation (now Lundbeck Inc.) in March 2009.
Lundbeck expects revenue of DKK 14.3-14.8 billion and EBIT of DKK 3.0-3.4 billion for 2010.
The Supervisory Board proposes to pay dividend of DKK 3.07 per share.